1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 What is This Report About? 10
3 In Vitro Diagnostics In Greece 11
3.1 In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017 11
3.2 In Vitro Diagnostics, Greece, Company share (2009-2010) 17
4 Clinical Chemistry In Greece 19
4.1 Clinical Chemistry Overall Revenue (2003-2017) 19
4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017) 23
4.1.2 Urine Analysis Revenue (2003-2017) 27
4.2 Clinical Chemistry Distribution Share (2009-2010) 31
4.3 Clinical Chemistry, Greece, Company share (2009-2010) 32
5 Genetic Testing In Greece 34
5.1 Genetic Testing Overall Revenue (2003-2017) 34
5.2 Genetic Testing Distribution Share (2009-2010) 38
5.3 Genetic Testing, Greece, Company share (2009-2010) 39
6 Haematology In Greece 41
6.1 Haematology Overall Revenue (2003-2017) 41
6.1.1 Haematology Reagents Revenue (2003-2017) 45
6.1.2 Immunohaematology Revenue (2003-2017) 49
6.1.3 Haemostasis Revenue (2003-2017) 53
6.1.4 Haematology Rapid Tests Revenue (2003-2017) 57
6.1.5 Haematology Cell Counters Revenue (2003-2017) 61
6.2 Haematology Distribution Share (2009-2010) 65
6.3 Haematology, Greece, Company share (2009-2010) 66
7 Histology And Cytology In Greece 68
7.1 Histology And Cytology Overall Revenue (2003-2017) 68
7.2 Histology And Cytology Distribution Share (2009-2010) 72
7.3 Histology And Cytology, Greece, Company share (2009-2010) 73
8 Immuno Chemistry In Greece 75
8.1 Immuno Chemistry Overall Revenue (2003-2017) 75
8.1.1 Disease Specific Immunochemistry Revenue (2003-2017) 79
8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 83
8.1.3 Endocrinology Tests Revenue (2003-2017) 87
8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017) 91
8.1.5 Immunochemistry Analyzers Revenue (2003-2017) 95
8.2 Immuno Chemistry Distribution Share (2009-2010) 99
8.3 Immuno Chemistry, Greece, Company share (2009-2010) 100
9 Infectious Immunology In Greece 102
9.1 Infectious Immunology Overall Revenue (2003-2017) 102
9.2 Infectious Immunology Distribution Share (2009-2010) 106
9.3 Infectious Immunology, Greece, Company share (2009-2010) 107
10 Microbiology Culture In Greece 109
10.1 Microbiology Culture Overall Revenue (2003-2017) 109
10.1.1 Microbiology Analyzers Revenue (2003-2017) 113
10.2 Microbiology Culture Distribution Share (2009-2010) 117
10.3 Microbiology Culture, Greece, Company share (2009-2010) 118
11 Overview of Key Companies in Greece In Vitro Diagnostics Market 120
11.1 F. Hoffmann-La Roche Ltd. 120
11.1.1 Company Overview 120
11.2 Siemens Healthcare 120
11.2.1 Company Overview 120
11.3 Abbott Laboratories 120
11.3.1 Company Overview 120
11.4 Beckman Coulter, Inc. 121
11.4.1 Company Overview 121
11.5 Ortho-Clinical Diagnostics Inc. 121
11.5.1 Company Overview 121
11.6 bioMerieux S.A. 121
11.6.1 Company Overview 121
11.7 Sysmex Corporation 122
11.7.1 Company Overview 122
11.8 Bio-Rad Laboratories, Inc. 122
11.8.1 Company Overview 122
11.9 Becton, Dickinson and Company 122
11.9.1 Company Overview 122
11.10 Phadia AB 123
11.10.1 Company Overview 123
11.11 DiaSorin S.p.A 123
11.11.1 Company Overview 123
11.12 DIAGNOSTICA STAGO, Inc. 123
11.12.1 Company Overview 123
11.13 PerkinElmer, Inc. 124
11.13.1 Company Overview 124
11.14 Thermo Fisher Scientific Inc. 124
11.14.1 Company Overview 124
11.15 Qiagen N.V. 124
11.15.1 Company Overview 124
11.16 Grifols, S.A. 125
11.16.1 Company Overview 125
11.17 HORIBA, Ltd. 125
11.17.1 Company Overview 125
11.18 Gen-Probe Incorporated 125
11.18.1 Company Overview 125
11.19 Immucor, Inc. 126
11.19.1 Company Overview 126
11.20 Life Technologies Corporation 126
11.20.1 Company Overview 126
11.21 Danaher Corporation 126
11.21.1 Company Overview 126
11.22 Hologic, Inc. 127
11.22.1 Company Overview 127
11.23 Cellestis Limited 127
11.23.1 Company Overview 127
12 Financial Deals Landscape 128
12.1 Partnerships 128
12.1.1 Biofortuna Enters Into Distribution Agreement With Abbott 128
12.1.2 Trinity Biotech Enters Into Distribution Agreement With A. Menarini
Diagnostics 129
13 APPENDIX 130
13.1 Global Markets Direct Research Methodology 130
13.2 Definitions of Markets Covered in the Report 131
13.2.1 In Vitro Diagnostics 131
13.3 Secondary Research 142
13.4 Primary Research 142
13.5 Models 143
13.6 Forecasts 143
13.7 Expert Panel Validation 143
13.8 Currency Conversion 144
13.9 Contact Us 144
13.10 Disclaimer 144
1.1 List of Tables
Table 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual,
2003-2017 12
Table 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual,
Historic, 2003-2010 14
Table 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual,
Forecast, 2010-2017 16
Table 4: In Vitro Diagnostics, Greece, Company share by Revenue ($m), USD
Actual, 2009-2010 18
Table 5: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 20
Table 6: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 22
Table 7: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 24
Table 8: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 26
Table 9: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 28
Table 10: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 30
Table 11: Clinical Chemistry, Greece, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 31
Table 12: Clinical Chemistry, Greece, Company share by Revenue ($m), USD Actual
2009-2010 33
Table 13: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 35
Table 14: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 37
Table 15: Genetic Testing, Greece, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 38
Table 16: Genetic Testing, Greece, Company share by Revenue ($m), USD Actual
2009-2010 40
Table 17: Haematology, Greece, Revenue ($m), USD Actual by Segment, Historic,
2003-2010 42
Table 18: Haematology, Greece, Revenue ($m), USD Actual by Segment, Forecast,
2010-2017 44
Table 19: Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 46
Table 20: Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 48
Table 21: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 50
Table 22: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 52
Table 23: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 54
Table 24: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 56
Table 25: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 58
Table 26: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 60
Table 27: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 62
Table 28: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 64
Table 29: Haematology, Greece, Distribution Share by Revenue ($m), USD Actual,
2009-2010 65
Table 30: Haematology, Greece, Company share by Revenue ($m), USD Actual
2009-2010 67
Table 31: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 69
Table 32: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 71
Table 33: Histology And Cytology, Greece, Distribution Share by Revenue ($m),
USD Actual, 2009-2010 72
Table 34: Histology And Cytology, Greece, Company share by Revenue ($m), USD
Actual 2009-2010 74
Table 35: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 76
Table 36: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 78
Table 37: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 80
Table 38: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 82
Table 39: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 84
Table 40: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 86
Table 41: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 88
Table 42: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 90
Table 43: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 92
Table 44: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 94
Table 45: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 96
Table 46: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 98
Table 47: Immuno Chemistry, Greece, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 99
Table 48: Immuno Chemistry, Greece, Company share by Revenue ($m), USD Actual
2009-2010 101
Table 49: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 103
Table 50: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 105
Table 51: Infectious Immunology, Greece, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 106
Table 52: Infectious Immunology, Greece, Company share by Revenue ($m), USD
Actual 2009-2010 108
Table 53: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 110
Table 54: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 112
Table 55: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 114
Table 56: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 116
Table 57: Microbiology Culture, Greece, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 117
Table 58: Microbiology Culture, Greece, Company share by Revenue ($m), USD
Actual 2009-2010 119
Table 59: Biofortuna Enters Into Distribution Agreement With Abbott 128
Table 60: Trinity Biotech Enters Into Distribution Agreement With A. Menarini
Diagnostics 129
Table 61: USD to Local Currency, Greece, Average Actual Rate 2003-2010 144
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual,
2003-2017 11
Figure 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual,
Historic, 2003-2010 13
Figure 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual,
Forecast, 2010-2017 15
Figure 4: In Vitro Diagnostics, Greece, Company share (%), 2010 17
Figure 5: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 19
Figure 6: Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 21
Figure 7: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 23
Figure 8: Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 25
Figure 9: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 27
Figure 10: Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 29
Figure 11: Clinical Chemistry, Greece, Company share (%), 2010 32
Figure 12: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 34
Figure 13: Genetic Testing, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 36
Figure 14: Genetic Testing, Greece, Company share (%), 2010 39
Figure 15: Haematology, Greece, Revenue ($m), USD Actual by Segment, Historic,
2003-2010 41
Figure 16: Haematology, Greece, Revenue ($m), USD Actual by Segment, Forecast,
2010-2017 43
Figure 17: Haematology Reagents, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 45
Figure 18: Haematology Reagents, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 47
Figure 19: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 49
Figure 20: Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 51
Figure 21: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 53
Figure 22: Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 55
Figure 23: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 57
Figure 24: Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 59
Figure 25: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 61
Figure 26: Haematology Cell Counters, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 63
Figure 27: Haematology, Greece, Company share (%), 2010 66
Figure 28: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 68
Figure 29: Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 70
Figure 30: Histology And Cytology, Greece, Company share (%), 2010 73
Figure 31: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 75
Figure 32: Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 77
Figure 33: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 79
Figure 34: Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 81
Figure 35: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 83
Figure 36: Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 85
Figure 37: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 87
Figure 38: Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 89
Figure 39: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 91
Figure 40: Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 93
Figure 41: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 95
Figure 42: Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 97
Figure 43: Immuno Chemistry, Greece, Company share (%), 2010 100
Figure 44: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 102
Figure 45: Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 104
Figure 46: Infectious Immunology, Greece, Company share (%), 2010 107
Figure 47: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 109
Figure 48: Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 111
Figure 49: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 113
Figure 50: Microbiology Analyzers, Greece, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 115
Figure 51: Microbiology Culture, Greece, Company share (%), 2010 118
Figure 52: Global Markets Direct Methodology 130
Companies Menstion
F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Sysmex Corporation
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
Phadia AB
DiaSorin S.p.A
DIAGNOSTICA STAGO, Inc.
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Qiagen N.V.
Grifols, S.A.
HORIBA, Ltd.
Gen-Probe Incorporated
Immucor, Inc.
Life Technologies Corporation
Danaher Corporation
Hologic, Inc.
Cellestis Limited
|
